Peptide library / Digestive & weight / Albiglutide
Albiglutide
A weekly GLP-1 receptor agonist that proved heart benefit but was withdrawn for business reasons.
Effects studied or claimed
What it is used or promoted for, and where each effect has actually been seen
- Blood sugar control in type 2 diabetesFDA approved
- Fewer major heart eventsLarge trials
How it is thought to work
Albiglutide fused two GLP-1 copies to human albumin, giving it a half-life of several days.
What the evidence shows
The Harmony Outcomes trial showed fewer major cardiovascular events than placebo.
Safety and unknowns
Injection site reactions and gastrointestinal effects.
Regulatory status
FDA-approved in 2014. Withdrawn by the manufacturer in 2018 for commercial reasons, not safety.
Regulatory status changes quickly. This entry was last reviewed on 27 October 2026. Confirm current status with the FDA before relying on it.
More in Digestive & weight
Amycretin
In clinical trialsAn investigational single molecule from Novo Nordisk that activates both GLP-1 and amylin receptors.
AOD-9604
Wellness and performanceA modified fragment of human growth hormone promoted for fat loss that did not work in large trials.
5-Amino-1MQ
Wellness and performanceA small molecule, not a peptide, sold alongside peptides for fat loss.
General information, not medical advice. Do not buy or inject unregulated peptides.